INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2015

A systematic review found no high-quality evidence that ascorbate supplementation enhances chemotherapy's antitumor effects or reduces its toxicity.

A systematic review of 34 studies evaluated the antitumor effects and toxicity of oral or intravenous ascorbate in cancer patients. Due to study heterogeneity, no meta-analyses were performed. No randomized controlled trials reported statistically significant improvements in overall or progression-free survival, or reduced toxicity, compared to control arms. Evidence suggesting antitumor effects was limited to case reports and observational or uncontrolled studies.

Study type
Systematic review
Who was studied
Cancer patients across 34 studies (5 RCTs [n = 322], 12 phase I/II trials [n = 287], 6 observational studies [n = 7,599], and 11 case reports [n = 267])
What was measured
Antitumor effects, overall survival, progression-free survival, and toxicity of ascorbate treatment

THE PAPER

Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.

Jacobs C, Hutton B, Ng T, Shorr R, Clemons M. Oncologist, 2015.

PubMed 25601965 ↗DOI 10.1634/theoncologist.2014-0381 ↗

CancerNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.